24 February 2020 - It is no secret that prescription drug prices are a hot-button issue — and understandably so.
When Donald Trump announced his desire to lower prescription drug prices at the this year’s State of the Union, House Democrats chanted “H.R.3,” in reference to House Bill 3, which aims to fulfill the president and the late Elijah Cummings' stated ambition at reducing drug prices. And yet the bill has sat in Mitch McConnell's legislative graveyard in the Senate since its passing through the House.
And then, one day after the SOTU, Secretary of Veterans Affairs Robert Wilkie delivered a gut punch to the pharmaceutical industry.